Recent reports show that EPHB4 is overexpressed in K562 cell line [10, 18], and high expression of EPHB4 is associated with imatinib resistance [9, 19] and dasatinib resistance [17], suggesting that EPHB4 may represent a potential target for CML therapy. This evidence concerns the gene EPHB4 and chronic myelogenous leukemia, BCR-ABL1 positive.